GlassScriptPhysician profile
Deepa B Verma
NPI 1225182918
$1,360.87
in general payments reported to CMS, 2019-2025
10 companies · $69.62 in 2025
The $69.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $183 · 2021: $675 · 2022: $106 · 2023: $44.25 · 2024: $91.94 · 2025: $69.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,019.67 | 2019-2025 | Xeomin |
| Aytu Biopharma, INC. | $113.17 | 2019-2020 | |
| Revance Therapeutics, INC. | $54.15 | 2025 | Daxxify |
| Cleerly, INC. | $37.17 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Ekos Corporation | $33.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.36 | 2023 | Cuvitru |
| Lilly USA, LLC | $29.18 | 2022 | |
| Galderma Laboratories, L.P. | $19.51 | 2022 | |
| Currax Pharmaceuticals LLC | $14.52 | 2022 | |
| Alexion Pharmaceuticals, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.